SPOTLIGHT -
Naeem Khan, MD: Ticagrelor Shines in Phase 3 THALES Trial
The vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases Portfolio detailed the results from the phase 3 THALES trial, and where ticagrelor stands among other FDA approved stroke treatments.